Glioma progression in diabesity

Mol Aspects Med. 2019 Apr:66:62-70. doi: 10.1016/j.mam.2019.02.002. Epub 2019 Mar 4.

Abstract

Diabetes mellitus, obesity, and cancer are diseases that in recent years have caused a large number of deaths worldwide, so have been in the front line of biomedical research. On the other hand, obesity is a risk factor for several types of cancer and type 2 diabetes mellitus. The metabolic disorder and global inflammatory environment seen in obese patients is also critical for the treatment of both diabetes mellitus and gliomas. Several molecules are increased in patients with obesity and are considered risk factors in the failure of multimodal therapies for diabetes mellitus and gliomas. These molecules include adenosine, insulin, adenosine deaminases, adenosine kinase, lipids, as well as adenosine receptors, adenosine membrane transporters, and the immune response. The role of adenosine will be explained in depth since it is a nucleoside aberrantly increased in patients with these diseases, is one of the main causes of diabetes mellitus progression and the failure of glioma therapies. In addition, the role of type 2 diabetes mellitus/obesity, i.e., diabesity, and its implication in glioma treatment is discussed.

Keywords: Diabesity; Diabetes; Glioblastoma; Glioma; Obesity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenosine / metabolism
  • Antineoplastic Agents / therapeutic use
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / metabolism*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / metabolism*
  • Disease Progression
  • Gene Regulatory Networks
  • Glioma / drug therapy
  • Glioma / metabolism*
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Obesity / complications*
  • Risk Factors
  • Up-Regulation

Substances

  • Antineoplastic Agents
  • Hypoglycemic Agents
  • Adenosine